Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer

Abstract Background Tumor mutation burden (TMB), DNA mismatch repair deficiency (dMMR), microsatellite instability (MSI), and PD‐L1 amplification (PD‐L1 AMP) may predict the efficacy of the PD‐1/PD‐L1 blockade. With the broadening landscape of immunotherapy use, it is important to identify patients...

Full description

Bibliographic Details
Main Authors:	Yuan‐sheng Zang, Chun Dai, Xiaoman Xu, Xin Cai, Guan Wang, Jinwang Wei, Angela Wu, Wending Sun, Shunchang Jiao, Qiang Xu
Format:	Article
Language:	English
Published:	Wiley 2019-08-01
Series:	Cancer Medicine
Subjects:	Chinese patients with cancer dMMR MSI PD‐L1 amplification TMB WES
Online Access:	https://doi.org/10.1002/cam4.2381

Similar Items

<i>WRN</i>-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
by: Kai Zimmer, et al.
Published: (2020-05-01)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
by: Qiao-Xuan Wang, et al.
Published: (2021-01-01)

Microsatellite instability: a review of what the oncologist should know
by: Kai Li, et al.
Published: (2020-01-01)

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
by: Jian Li, et al.
Published: (2021-06-01)

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
by: Edouard Auclin, et al.
Published: (2021-07-01)

An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population—A Bi-Institutional Pilot Study
by: Cristina Lungulescu, et al.
Published: (2021-08-01)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
by: Claudio Luchini, et al.
Published: (2020-10-01)

Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines
by: Vladimir Roudko, et al.
Published: (2021-09-01)

Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody
by: Wenyue Zhou, et al.
Published: (2021-09-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2
by: Ling Ye, et al.
Published: (2017-06-01)

Screening and Prognostic Value of Methylated Septin9 and its Association With Clinicopathological and Molecular Characteristics in Colorectal Cancer
by: Jie Sun, et al.
Published: (2021-05-01)

Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
by: T. T. Andabekov, et al.
Published: (2019-07-01)

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker
by: Xinyao Hu, et al.
Published: (2021-10-01)

Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role
by: Hua Zhu, et al.
Published: (2021-09-01)

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
by: Xin Cheng, et al.
Published: (2021-02-01)

Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors
by: Salman M. Toor, et al.
Published: (2021-01-01)

Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results
by: Shamekh R, et al.
Published: (2016-08-01)

Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
by: Maria C. Svensson, et al.
Published: (2019-03-01)

Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer
by: Li Zhang, et al.
Published: (2021-05-01)

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
by: Luigi Della Gravara, et al.
Published: (2021-06-01)

Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens
by: Toshiaki Akahane, et al.
Published: (2020-07-01)

Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
by: Huijuan Ge, et al.
Published: (2021-02-01)

Patterns of germline and somatic mutations in 16 genes associated with mismatch repair function or containing tandem repeat sequences
by: Shih‐Ching Chang, et al.
Published: (2020-01-01)

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy
by: Shuhang Wang, et al.
Published: (2021-02-01)

Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions
by: Rita T. Lawlor, et al.
Published: (2021-06-01)

Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China
by: Xiangyan Zhang, et al.
Published: (2018-02-01)

The Mismatch Repair System (MMR) in Head and Neck Carcinogenesis and Its Role in Modulating the Response to Immunotherapy: A Critical Review
by: Maria Cilona, et al.
Published: (2020-10-01)

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
by: Haibo Mou, et al.
Published: (2018-11-01)

Mismatch Repair Pathway, Genome Stability and Cancer
by: Nives Pećina-Šlaus, et al.
Published: (2020-06-01)

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
by: Yaxiong Zhang, et al.
Published: (2019-04-01)

Immunotherapy in Colorectal Cancer: Current and Future Strategies
by: Akira Ooki, et al.
Published: (2021-01-01)

The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
by: Yanhui Chen, et al.
Published: (2020-08-01)

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
by: Yao Chen, et al.
Published: (2020-09-01)

Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma
by: Chaoqi Zhang, et al.
Published: (2020-09-01)

Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report
by: Katsuo Usuda, et al.
Published: (2020-06-01)

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
by: Xiaoliang Liu, et al.
Published: (2019-08-01)

Coexistence of atypical adenomatous hyperplasia, minimally invasive adenocarcinoma and invasive adenocarcinoma: Gene mutation analysis
by: Junya Song, et al.
Published: (2021-03-01)

Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting
by: Umberto Malapelle, et al.
Published: (2021-07-01)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
by: Ye Wang, et al.
Published: (2021-06-01)